Our observations and others showing that eliminating FAP-positive CAFs in immunocompetent mouse models increased CD8+ tumor-infiltrating lymphocytes suggest that FAP-targeted therapies represent a strategy for enhancing the immune anti-tumor response12,13. The gene discussed is CD8A; the disease is neoplasm.